The dose-response effect of aerobic exercise on inflammation in colon cancer survivors.
Front Oncol
; 13: 1257767, 2023.
Article
in En
| MEDLINE
| ID: mdl-38148846
ABSTRACT
Background:
Physical activity after surgical resection for colon cancer is associated with significantly longer disease-free survival. Inflammation is hypothesized to mediate the association between physical activity and disease-free survival in colon cancer.Methods:
In this exploratory analysis of a randomized dose-response trial, 39 colon cancer survivors who completed standard therapy were stratified by cancer stage and randomized in a 111 ratio to one of three treatment groups for 24 weeks of usual-care control, 150 min/wk of moderate-intensity aerobic exercise (low-dose), or 300 min/wk of moderate-intensity aerobic exercise (high-dose). Inflammation outcomes included high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL6), and soluble tumor necrosis factor-alpha receptor 2 (sTNFαR2). Mixed models for repeated measures were used to test the hypothesis that exercise was associated with dose-response reductions in inflammation; exploratory analyses examined treatment effects by cancer stage.Results:
In the overall population, aerobic exercise was not associated with dose-response reductions in hs-CRP, IL6, or sTNFαR2. Cancer stage modified the association between randomized group and hs-CRP (P=0.022) and IL6 (P<0.001) but not sTNFαR2 (P=0.39). In stage I-II disease, compared to control, exercise was not associated with inflammation outcomes. In stage III disease, compared to control, low-dose exercise reduced hs-CRP -35.4% (95% CI -70.1, -0.7) and IL6 -29.6% (95% CI -58.4, -0.8) but not sTNFαR2 2.7% (95% CI sTNFαR2 -15.7, 21.1); high-dose exercise was not associated with inflammation outcomes in stage III disease.Conclusion:
This exploratory analysis offers preliminary data to support the hypothesis that inflammation may mediate the association between physical activity and disease-free survival in colon cancer. Clinical trial registration clinicaltrials.gov, identifier NCT02250053.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Front Oncol
Year:
2023
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Suiza